Safety and Efficacy Study of Polydioxanone (PDS) Plates in Rhinoplasty

Rhinoplasty Clinical Trial

Official title:

An Open-Label, Randomized, 2-Arm Parallel Study Comparing the Efficacy, Ease of Use, and Safety of PDS Plated Cartilagenous Grafting Versus Non-Plated Cartilagenous Grafting as Performed Through Endonasal Rhinoplasty

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01225250
• Other study ID #: PDS-END-001
• Status: Completed
• Phase: N/A
• Start date: November 24, 2010
• Est. completion date: January 19, 2015

Study information

• Verified date: October 2020
• Source: DeNova Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine efficacy, safety, and ease of cartilaginous grafting using polydioxanone (PDS) plates in comparison to non-plated cartilaginous grafts as performed through an endonasal rhinoplasty approach in patients requiring a caudal septal extension (CSE) graft.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: January 19, 2015
• Est. primary completion date: January 19, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males and females between 18 and 65 years of age.

• Subjects requesting primary or secondary rhinoplasty and requiring a CSE graft performed through an endonasal approach.

• Subjects willing to undergo PDS plating.

• Subjects with either ear conchal or septal cartilage available for grafting purposes.

• Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.

• Willingness and ability to comply with the PI's standard preoperative and postoperative rhinoplasty instructions.

• Subjects of childbearing potential must have a negative urine pregnancy test result at Visit 1 and be willing able to use an acceptable method of birth control (e.g., barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following is documented on the medical history:

• postmenopausal for at least 12 months prior to study drug administration

• without a uterus and/or both ovaries

• has had a bilateral tubal ligation for at least 6 months prior to study drug administration.

• absence of an other physical condition according to the PI's discretion

• Willingness and ability to provide written photo consent and adherence to photography procedures (i.e., removal of jewelry and makeup).

• Willingness and ability to provide written informed consent prior to performance of any study related procedure.

Exclusion Criteria:

• Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control.

• Subjects with a significant systemic illness or illness localized to the areas of treatment.

• Subjects with previous history of nasal implants.

• Subjects with previous or current history of nasal infections.

• Subjects who have history of blood thinners (aspirin, ibuprofen, naprosyn, herbal supplements, Vitamin E) within the two weeks prior to surgery.

• Subjects who have smoked within the two weeks prior to surgery.

• Subjects who have had alcohol or illicit drugs one week prior to surgery.

• Subjects who have eaten or drank anything after midnight the night prior to surgery.

• Subjects with current history of chronic drug or alcohol abuse.

• History of autoimmune disease.

• Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication.

• Subjects who anticipate the need for surgery, other than the study procedure, or overnight hospitalization during the study.

• Subjects who, in the Investigator's opinion, have a history of poor cooperation, non compliance with medical treatment or unreliability.

• Enrollment in any active study involving the use of investigational devices or drugs.

Related Conditions & MeSH terms

• Rhinoplasty

Intervention

Device:
• Polydioxanone (PDS) plates
0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.

Procedure:
• Caudal septal extension graft performed through endonasal rhinoplasty
The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
• Caudal septal extension graft performed through endonasal rhinoplasty
The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.

Locations

Country	Name	City	State
United States	DeNova Research	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
DeNova Research	Mentor Worldwide, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Live Assessment of Satisfaction With the Grafts	Efficacy will be determined by a live assessment of satisfaction with the grafts at 12 months using a four-point categorical satisfaction scale ((4) unsatisfied, (3) satisfied, (2) very satisfied, (1) highly satisfied).; Scores closer to 1 indicate a more favorable outcome	12 months post operative
Primary	Assessment of Tip Projection	Tip projection will be measured using standardized photography preoperatively and at 1 month, 3 months, 6 months, and 12 months postoperatively using Goode's Ratio.; The ratio of the line from the alar crease to the nasal tip to the nasion to the nasal tip should be 0.55. If it is more than that the nose is over projected, if it is under that ratio the nose is under projected.	12 months Post opeartive
Primary	Non-treating Blinded Evaluator Satisfaction Assessment	A non-treating blinded evaluator will assess satisfaction with a four-point categorical satisfaction scale ((4) - unsatisfied, (3) - satisfied, (2) - very satisfied, (1) - highly satisfied) of subject's grafts using photographs from baseline, 1 month, 3 months, 6 months, and 12 months and will consist of a blinded evaluation in which the physician is aware of the type of graft, but unaware of plating status or the specific grafting site.; Scores closer to 1 indicate a more favorable outcome	Assessed at baseline, 1 month, 3 months, 6 months, and 12 months; Month 12 reported
Primary	Ease of Use	Ease of use will be determined by the treating investigator using a 10 cm Visual Analog Scale (VAS) to demonstrate technical ease with a score of 0 mm being easy and a scale of 100 mm being extremely difficult.	1 hour following surgery
Secondary	Number of Participants With Infection, Rejection, and Extrusion of the Graft at 1 Week, 1 Month, 3 Months, 6 Months, and 12 Months	Safety will be determined by rate of infection, rejection, and extrusion of the graft at 1 week, 1 month, 3 months, 6 months, and 12 months.	12 months post surgery
Secondary	Intraoperative Duration	The intraoperative duration of the grafting procedure will be measured by an assistant using a stopwatch to record the time it takes to harvest, shape, and satisfactorily secure the graft.	During surgery (up to 3 hours)

External Links

•   DeNova Research
•   Dr. Steven H. Dayan, MD FACS